PB1996 PROGNOSTICATION OF HODGKIN'S LYMPHOMA BY IPET AND IPS: UPDATE DATA OF 8 HEMATOLOGICAL UKRAINIAN CENTERS
Background: PET‐CT has completely changed and improved treatment approaches in patients with Hodgkin Lymphoma (HL) for the last years. Recent studies are evaluated predictive role PET for survival rate. The major idea is to identify patients from a high‐risk group who can have early relapse/refracto...
Saved in:
| Published in: | HemaSphere Vol. 3; no. S1; pp. 903 - 904 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
01-06-2019
|
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background:
PET‐CT has completely changed and improved treatment approaches in patients with Hodgkin Lymphoma (HL) for the last years. Recent studies are evaluated predictive role PET for survival rate. The major idea is to identify patients from a high‐risk group who can have early relapse/refractory disease using iPET and IPS to guide the choice of chemotherapy.
Aims:
To evaluate the prognostic role of iPET in patients with HL.
Methods:
The cohort consisted of 132 patients of up to 69 years of age with newly diagnosed HL were treated with ABVD or BEACOPP‐14/esc based on their stage and risk group. Metabolic PET‐CT imaging was performed to routine protocols using Deauville criteria for response assessment. Interim PET was performed at 15.5 ± 3 days (range, 5‐26) after 2‐3d and 4th cycles of treatment in 81% and 19% cases, respectively (p < 0.05). The main endpoints of study were to assess the correlation between IPS, iPET findings and clinical outcome (relapse/death).
Results:
The ORR (CR, PR) in this group of patients was 85.6%. The maximum follow‐up period was 70 months (median 16 months). Under the follow‐up there are still 96.9% (128/132) patients.
81.8% (108/132) and 18.2% (24/132) of patients had 1–3 and 4–5 scores of iPET by Deauville 5‐PS scale, respectively (p < 0.05). In total, disease progression was documented in 20.8% (5/24) iPET‐positive (iPET+) and 13% (14/108) iPET‐negative (iPET‐) patients (p < 0.05). There were two deathss from refractory disease. The 5‐year EFS of iPET+ patients vs iPET‐was 50% and 80%, respectively (p < 0.05).
We divided patients by IPS groups: 71(53.8%) with ≤2 and 61(46.2%) with ≥3 risk factors (low and high‐risk group, respectively, p < 0.05).Patients in low‐risk group were associated with significant improvement in 5‐year EFS compared with patients in high‐risk group (80% vsthe 65%, respectively, longrank test, p = 0.01).The estimated 5‐year EFS was 80% in iPET‐ vs 65% with iPET+ in low risk group (p < 0.05). The 5‐year EFS was significantly better in high‐risk patients who achieved iPET‐ status compared to iPET+ status (70% vs 55%, p < 0.05).
Summary/Conclusion:
In our study, we found that IPS correlates with iPET results. Moreover, it could predict treatment outcomes in patients with HL. |
|---|---|
| ISSN: | 2572-9241 2572-9241 |
| DOI: | 10.1097/01.HS9.0000566476.65944.55 |